References

Aldosterone and cardiovascular diseases

10.1093/cvr/cvac027 · 2023 · External reference

Adverse effects of aldosterone: beyond blood pressure

10.1161/jaha.123.030142 · 2024 · External reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure

10.1056/nejm199909023411001 · 1999 · External reference

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

10.1056/nejmoa030207 · 2003 · External reference

Finerenone in heart failure with mildly reduced or preserved ejection fraction

10.1056/nejmoa2407107 · 2024 · External reference

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

10.1093/eurheartj/ehab777 · 2022 · External reference

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

10.1016/s0140-6736(15)00257-3 · 2015 · External reference

10.1093/eurheartj/ehag440 · 2026 · Admitted local publication

Interaction between aldosterone and mineralocorticoid receptor antagonist: findings from the EPHESUS trial

10.1016/j.jchf.2025.02.025 · 2025 · External reference

Primary aldosteronism: an Endocrine Society clinical practice guideline

10.1210/clinem/dgaf284 · 2025 · External reference

Biomarkers to guide medical therapy in primary aldosteronism

10.1210/endrev/bnad024 · 2024 · External reference

Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry

10.1016/j.jacc.2018.04.070 · 2018 · External reference

Increasing the potassium level in patients at high risk for ventricular arrhythmias

10.1056/nejmoa2509542 · 2025 · External reference

Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases

10.1210/clinem/dgae823 · 2025 · External reference

Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017

10.1002/ejhf.2418 · 2022 · External reference